Biotech Values

[ghmm]

For what its worth United had Phase 2 Data of OvaRex presented at ASCO in combination with Chemo (for Front-line Ovarian Cancer) and prior phase 2 work in recurrent ovarian cancer in combination with chemo both showing a synergistic immune response.

I am more negative then positive on the Phase 3 IMPACT studies (watchful waiting period administration of OvaRex). I think the data gathered thus far may lead to further studies in using immuno-therapy in conjunction with chemotherapy. It seems a bit counterintuitive to me but perhaps there is more to it if several companies are discovering similar results.